21 June 2019 - Only once-daily PARP inhibitor approved in Europe for hereditary breast cancer.

Pfizer today announced that the European Commission approved Talzenna (talazoparib), an oral poly (ADP-ribose) polymerase (PARP) inhibitor, as monotherapy for the treatment of adult patients with germ-line breast cancer susceptibility gene 1/2-mutations, who have human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer. 

Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.

This approval follows the medicine’s approval by the U.S. FDA in October 2018.

Read Pfizer press release